Loading…
Employees: 2,110
Size Shanghai Haohai Biological Technology (6826.HK) is a Hong Kong Health Care company (Medical Distributors) with a market value of $926M, the 612th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$16.01 on 6 Nov 2026.
Performance Over six months the shares fell 27.2%, against 0.0% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 4.9% over the last twelve months (peer median +4.7%); the operating margin is -1.9% (peer median 2.3%).
Valuation It trades at 7.9× forward earnings against a peer median of 15.3× (cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.0 points below its cost of capital (7.7% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$2.59B | HK$2.67B | HK$2.91B | HK$2.92B | HK$2.46B |
| Revenue growth | — | -8% | 0% | +19% | — |
| Gross profit | HK$1.81B | HK$1.74B | HK$1.89B | HK$1.92B | HK$1.54B |
| EBITDA | n/a | HK$494M | HK$629M | HK$660M | HK$433M |
| Net income | HK$128M | HK$272M | HK$456M | HK$460M | HK$210M |
| Free cash flow | HK$306M | HK$497M | HK$393M | HK$444M | -HK$39.6M |
| Capital expenditure | HK$235M | HK$203M | HK$394M | HK$295M | HK$369M |
| Total debt | HK$507M | HK$444M | HK$482M | HK$449M | HK$133M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6826.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.3% | +0.3% | 8th highest of 21 |
| 6-month return | -27.2% | 0.0% | 4th lowest of 21 |
| Distance from 52-week high | -43.4% | -18.4% | 4th lowest of 21 |
| Revenue growth (TTM) | -4.9% | +4.7% | 4th lowest of 21 |
| Operating margin | -1.9% | 2.3% | 3rd lowest of 21 |
| Forward P/E | 7.9× | 15.3× | cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 17.2% | -0.4% | 3rd most demanding of 17 |
| Growth delivered (Del g) | +12.4% | +5.4% | 3rd highest of 17 |
| Hurdle (Req g minus delivered) | +4.8 pp | -6.2 pp | 4th most demanding of 17 |
| ROIC minus cost of capital | -5.0 pp | +0.4 pp | 6th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $926M | -27% | -5% | -2% | 7.9× | 17.2% | +12.4% |
| Entero Healthcare Solutions ENTERO.NS | India | $875M | +50% | +32% | 4% | 46.5× | 21.8% | +29.9% |
| Guangxi LiuYao 603368.SS | China | $994M | +2% | +2% | 5% | 9.9× | -9.5% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $1.02B | +48% | 0% | 8% | 21.3× | -1.3% | +3.9% |
| DocMorris DOCM.SW | Switzerland | $1.02B | +136% | +11% | -8% | n/a | n/a | n/a |
| Nanjing Pharmaceutical 600713.SS | China | $1.03B | +1% | +3% | 2% | n/a | n/a | n/a |
| Neuca NEU.WA | Poland | $817M | -1% | +8% | 2% | 15.3× | 5.0% | +8.1% |
| AS ONE 7476.T | Japan | $1.08B | +15% | +10% | 12% | 18.2× | -1.0% | +6.3% |
| Shinva Medical Instrument 600587.SS | China | $1.16B | -7% | +6% | 5% | 14.2× | -5.9% | +1.2% |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.20B | -28% | +8% | 3% | n/a | -1.3% | +17.9% |
| Ship Healthcare 3360.T | Japan | $1.34B | +4% | +7% | 3% | 13.8× | -14.7% | +7.6% |
| Shanghai New World 600628.SS | China | $623M | -11% | -2% | 6% | n/a | 0.3% | +1.0% |
| GKHT Medical Technology 301370.SZ | China | $569M | -22% | -11% | 1% | n/a | 14.4% | +7.5% |
| Arata 2733.T | Japan | $552M | -7% | +3% | 1% | 11.9× | -7.1% | +3.8% |
| Toho 8129.T | Japan | $1.60B | -14% | +4% | 1% | 21.6× | -7.4% | +5.1% |
| Redcare Pharmacy RDC.DE | Germany | $1.63B | +52% | +19% | 0% | n/a | n/a | n/a |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $517M | -21% | +10% | 0% | n/a | 12.2% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $501M | -29% | -41% | -17% | n/a | n/a | n/a |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $475M | -60% | -22% | -1% | n/a | 59.0% | -7.8% |
| Vital KSK 3151.T | Japan | $428M | +7% | +2% | 1% | n/a | 0.4% | +2.6% |
| Excelsior Medical 4104.TW | Taiwan | $409M | +1% | +6% | 8% | n/a | 2.9% | +5.7% |